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Abstract Everolimus is indicated for adults with metastatic
renal cell carcinoma (mRCC) after failure of vascular endothe-
lial growth factor receptor-tyrosine kinase inhibitors (TKI).
Currently, the therapeutic applicability of EVE has been chang-
ing. Multicenter evaluation of efficacy and safety of everolimus
in daily routine and definition of patient characteristics with
favorable outcome. Data of 165 patients from 9 oncology insti-
tutes in Hungary were analyzed retrospectively. Everolimus
therapy was used after one TKI in 10 mg starting dose.
Physical and laboratory examinations and imaging tests were
performed monthly and every 3 months, respectively. Median
progression-free survival (PFS) was 5.4 months. Median overall
survival (OS) was 16.2 months. PFS and OS results were more
favorable in patients with ECOG 0–1 (pPFS = 0.033,
pOS = 0.008) and after >9 months of TKI therapy
(pPFS = 0.019, pOS = 0.045). Survival was longer in nonanemic
patients with ECOG 0–1 than in anemic patients with ECOG 2–
3, 30.9 and 7.7months, respectively (p = 0.029). Dose reduction
and treatment delay was required in 6.2% and 8.9% of patients,
respectively. Common adverse events were exanthema, edema,
stomatitis, anemia, and abnormal kidney functions and glucose
levels. Results of this study show that everolimus is safe and
efficacious in a real-world setting. Everyday practice showed
that nonanemic patients with good performance status receiving
TKI therapy for >9 months are favorable candidates for this
treatment. Despite the efficiency of novel, registered drugs,
everolimus still plays an important role during and after
second-line therapy for mRCC when availability of modern
remedies is limited.
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Introduction
Everolimus (Afinitor®, Novartis) (EVE), an oral mammalian
target of rapamycin (mTOR) inhibitor, has been evaluated in
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preclinical studies and in numerous clinical trials in the past
decade [1]. PI3K/AKT/mTOR is an intracellular signaling path-
way in which mTOR is a protein kinase involved in the regula-
tion of several cellular functions such as proliferation, growth
and survival [2]. This mentioned pathway plays a central role in
tumorigenesis of renal cell cancers (RCC) [3]. The anti-tumor
effect of EVE had been confirmed in the therapy of advanced or
metastatic RCC (mRCC), and then neuroendocrine tumors of
pancreatic origin, of other gastrointestinal or lung origin, and
hormone receptor-positive advanced breast cancers [4–7].
The first registration study of EVE was a phase 3 placebo-
controlled study for the treatment of advanced RCC (RECORD-
1), in which the patients’ disease has previously progressed on
or after sunitinib and/or sorafenib therapy. Progression-free sur-
vival (PFS) was significantly longer in patients who received
EVE than those who received placebo (4.9 months vs
1.9 months) [4]. The difference between the overall survival
(OS) of the two arms was equalized due to crossover after pro-
gression (14.8 months with EVE vs 14.4 months with placebo)
[8]. The results of the subgroup after failure on one line vascular
endothelial growth factor receptor (VEGFR) tyrosine kinase
inhibitor (TKI) therapy demonstrated more favorable PFS
(5.4 months) [9]. According to the international guidelines
(e.g., NCCN, ESMO, EAU), EVE can be used to treat patients
with mRCC whose condition progressed during or after anti-
VEGFR TKI [10–12].
Currently, the therapeutic administration of EVE has been
changing. The results of one new phase 2 and two phase 3
studies have been published in the past two years with respect
to mRCC, in which EVEwas the comparator of the investigated
drugs. The survival rates were more favorable in the immune
checkpoint inhibitor nivolumab, TKI cabozantinib, and also in
the tri-specific targeted VEGFR-, RET- and fibroblast growth
factor receptor (FGFR) inhibitor lenvatinib combined with the
EVE arms compared to EVE administered alone [13–16]
[Table 1]. According to the recent guidelines, the role of EVE
should be amended in the clinical practice [17].
Besides the therapeutic efficiency of novel remedies, the
availability of new therapeutic options also influences the sur-
vival of oncologic patients. In some economic regions, the fi-
nancing of new therapies with high cost is limited, so in the
everyday practice, the oncologist has to maximize the efficiency
of new therapeutic options with the available resources.
Aim of our study was to retrospectively analyze the max-
imal efficiency and the side-effects of EVE in the everyday
practice of different oncology centers. We wished to define
patient characteristics which made the therapy more effective.
Patients and Methods
Patients Everolimus was administered to 165 patients with
mRCC between January 2010 and December 2013 in nine
Hungarian oncological institutes. The study was performed
in accordance with the Hungarian drug law and relevant
guidelines of the Hungarian health authorities. The study
design was approved by the ethics committee (registration
number WHO 3483).
Patients were administered everolimus after they had
progressed mostly on sunitinib, and in some cases on sorafe-
nib or pazopanib therapy. Histological and staging examina-
tions, such as abdominal and chest CT (if clinically indicated,
bone scintigraphy and skull CT) were performed before initi-
ating the therapy. 71% of the patients had a comorbidity that
required treatment.
Everolimus Therapy Everolimus 10 mg daily was adminis-
tered orally in continuous 28-day cycles. Aminimumwashout
period of 4 weeks followed the previously administered anti-
VEGFR therapy. Treatment was started when patients’ gener-
al condition was good; they did not suffer from side-effects of
the previous therapies, and after stabilization of symptoms
caused by new metastases (e.g., cerebral metastasectomy,
brain or bone irradiation, anemia control, etc.). Dose reduction
Table 1 Second and third line
clinical trials with everolimus in
clear cell renal cell cancer
Trial, Author Phase N Arms mPFS (months) ORR (%) mOS (months)
RECORD-1
Motzer et al. [4, 8]
III 416 EVE 4.9 2 14.8
PBO 1.9 0 14.4 (crossover)
CheckMate 025
Motzer et al. [13]
III 821 NIVO 4.6 25 25.0
EVE 4.4 5 19.6
METEOR
Choueiri et al. [14, 15]
III 658 CABO 7.4 17 21.4
EVE 3.9 3 16.5
Motzer et al. [16] II 151 LEN + EVE 14.6 43 25.5
LEN 7.4 27 18.4
EVE 5.5 6 17.5
CABO cabozantinib, EVE everolimus, LEN lenvatinib, mOS median overall survival, mPFS median progression
free survival, NIVO nivolumab, ORR overall response rate, PBO placebo
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or delay was performed according to the Summary of Product
Characteristics [1]. Physical examination and laboratory tests
were performed every 4 to 8 weeks. Imaging examinations
were performed 8 weeks after the initiation of everolimus
therapy, and once every twelve weeks thereafter, as indicated
by the National Health Insurance. Tumor response was eval-
uated every 12 weeks according to RECIST 1.0 [18]. Severity
of AEs was evaluated based on the National Cancer Institute
Common Terminology Criteria for Adverse Events, Version
3.0 (88% in case of 145 patients) [19]. The patients’ general
condition was assessed according to ECOG scale [20]. After
progression on everolimus, treatment in clinical studies, ther-
apy with interferon, progesterone derivatives, and best sup-
portive care were available as therapeutic options. Our data
were collected retrospectively.
Statistical Analysis Statistical analyses were performed by
using SPSS 20.0 for Windows (SPSS Inc., Chicago, IL,
USA). The association between PFS, OS and age was
analyzed using COX regression. The influence of other
therapy-related factors (duration of TKI therapy and the time
that elapsed between the cessation of TKI therapy and the
initiation of everolimus), and patient-related factors (gender,
type of previous therapy, ECOG status, and anemia) on PFS
and OS was analyzed with Kaplan-Meier analysis.
Results
Patient CharacteristicsOut of the 165 patients who partic-
ipated in the study, 76.4% were men and 23.6% were wom-
en [Table 2]. The mean age was 63.2 (range, 28–79) years,
and 93.9% of patients had undergone nephrectomy. The
general condition of the patients was good with 27.9%
and 63.6% of patients having ECOG scores of 0 and 1,
respectively; 6.1% and 2.1% of patients had ECOG scores
of 2 and 3, respectively. Common comorbidities were hy-
pertension, other cardiovascular disorders, and diabetes.
Table 2 Patient characteristics
Patients
N = 165
Mean age, years ± SE 63.2 ± 0.9
Age range, years 28–79
n %
Gender Male 126 76.4
Female 39 22.6
ECOG 0 46 27.9
1 105 63.6
2 10 6.1
3 4 2.1
Comorbidities n %
Hypertension 66 40.0
Other cardiovascular disorders 16 9.7
Diabetes 18 10.9
Secondary tumors 13 7.9.
Hematological disease 4 2.4
Asthma 4 2.4
Psoriasis 3 1.8
Metastases
Mean number of metastatic sites (range) 2.4 (1–6)
Location of metastases n %
Lung 142 86.0
Bone 67 40.6
Distant lymph node 60 36.4
Liver 31 18.8
Brain 21 12.7
Suprarenal gland 15 9.1
Other (peritoneum, pleura, pancreas, local relapse, contralateral kidney, thyroid gland) – ‹8
Histopathological types n %
Purely clear cell renal cell type (ccRCC) 146 88.5
ccRCC with sarcomatoid morphology 9 5.45
ccRCC with papillary- / chromophobe- / both morphology 2 / 2 / 2 1.2 / 1.2 / 1.2
ccRCC with sarcomatoid + papillary- / chromophobe- / or both morphology 1 / 1 / 1 0.6 / 0.6 / 0.6
ccRCC with collecting duct component 1 0.6
ECOG Eastern Cooperative Oncology Group, n number of involved patients, N number of analyzed patients,
ccRCC clear cell renal cell cancer, SE standard error
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The mean number of metastatic sites was 2.4 (range, 1–6),
and the most common sites of metastasis were the lungs,
bones, distant lymph nodes and the liver. The histological
type of the tumors was mainly clear cell renal cell cancer
(ccRCC) in case of all patients, in most cases pure ccRCC.
No rare variants could be detected, only sarcomatoid, pap-
illary, chromophobe or collecting duct morphologies and
transformations in the ccRCC were present [Table 2].
No genetic analyses were performed to prove the familial
origin of the renal cancer. Renal cancer has developed in 11
(7.27%) and in 3 (1.8%) patients under 50 and 40 years of age,
respectively. In these cases, there was no information about
any benign tumor, paraganglioma, pheochromocytoma or bi-
lateral tumor. Familial origin and multifocality could be ob-
served in 1 and 2 cases, respectively. Bilateral renal cancer and
secondary malignancy (3 rectal cancers, 2 CLLs, 1 breast
cancer) could be detected in 5 and 6 cases, respectively.
Previous Therapies After undergoing nephrectomy, 9.1% of
the patients received adjuvant INF treatment, and 4.8% of
patients received IFN before the administration of VEGFR-
targeted therapy. Before receiving everolimus, 93.9%, 4.8%,
and 1.2% of patients were given sunitinib, sorafenib, and
pazopanib, respectively. The mean (±SE) duration of TKI
therapy was 11.7 (±0.9) months. The duration of TKI was
<3 months in 15.7% of patients, who were defined as being
resistant to primary TKI therapy [21]. The mean (±SE) dura-
tion between the end of TKI therapy and the beginning of
everolimus was 97. 7 (±10.1) days (period between TKI–
EVE) [Table 3].
Dose Parameters Overall, 6.2% of the patients required a
dose reduction to manage pneumonitis (4.1%), grade 2 skin
problems (1.4%), and face and neck edema (0.7%).
Furthermore, 8.9% of the patients required a dose delay with
a mean duration of 24 (range, 5–75) days. The reasons for
delaying the dose for >7 days were cardiovascular symptoms,
elevation of renal functions that required dialysis (10 days
each), grade 3 diarrhea (9–14 days), cerebral metastasectomy
(20 days), and pneumonitis in 2 cases (28 and 30 days).
Efficacy At the time of the analysis, 26.2% of the patients
were being treated, and 53.8% of the patients were alive.
Partial regression, stable disease, and progression occurred
in 12.9%, 60.7% and 26.4% of the patients, respectively. No
patients experienced complete regression (CR). The objective
tumor response was 12.9%, and the clinical benefit rate was
73.6% (partial regression + stable disease). Themedian PFS at
a median follow-up time of 21.2 months (95%CI 7.05–31.45)
was 5.4 months (95%CI 3.83–6.97). The median overall sur-
vival time (OS) (based on data from 145 patients) was
16.2 months (95%CI 12.95–19.45).
AEs The most common AEs were exanthema (25%), periph-
eral edema (19%), stomatitis (19%), pneumonitis (13%), nau-
sea, weight loss, fatigue (11% each), diarrhea (10%), dyspnea
(10%), and mucositis (9%). The most common abnormalities
identified in laboratory findings were anemia (72%), and ele-
vation in renal function (45%), liver function (25%), blood
glucose (51%), cholesterol (44%) and lipids (35%). AEs com-
pared with data from the phase III study are presented in
Table 4. No severe or life threatening AEs occurred.
Table 3 Previous therapies
before everolimus treatment Patients
N = 165
Previous therapies n %
Nephrectomy 155 93.9
Adjuvant IFN 22 13.3
First line IFN before VEGFR-TKI 21 12.7
Sunitinib 155 93.9
Sorafenib 8 4.8
Pazopanib 2 1.2
First line VEGFR-TKI 157 95.1
Second line VEGFR-TKI after IFN 8 4.8
Duration of previous therapy
Mean duration of VEGFR-TKI, months (±SE) 11.7 (±0.9)
Duration of VEGFR-TKI <3 months, n (%) 26 15.7
Mean duration between VEGFR-TKI and EVE, days (±SE) 97.7 (±10.1)
EVE everolimus, IFN interferon-α, n number of involved patients, N number of analyzed patients, SE standard
error, TKI tyrosine kinase inhibitor, VEGFR vascular endothelial growth factor receptor
A. Maráz et al.
Author's personal copy
Factors Influencing Efficacy PFS and OS with everolimus
were not influenced by the patients’ gender, age, the number
and type of metastatic organ systems, the presence of the me-
tastasis only in the lungs, the length and type of the previous
TKI therapy, or the time between the cessation of TKI treat-
ment and initiating everolimus.
Patients without lung metastasis showed favorable out-
come (PFS 5.3 vs 9.1 months p = 0.042, OS 10.3 vs
15.9 months p = 0.006) [Table 5].
Median PFS and OS of patients treated with TKI therapy
≤3 months, vs > 3 months were 3.0 vs 5.2 months and 16.0 vs
19.9 months, respectively; however, the differences were not
Table 4 Adverse events of patients who received everolimus
Most common adverse events Hungarian analysis RECORD-1 Registration study [4]
n = 145 n = 269
All grade % Grade 2% Grade 3% All grade % Grade 3/4%
Exanthema (rash) 25 5 1 29 1/0
Peripheral edema 20 – 1 25 <1 / 0
Stomatitis 24 2 – 44 4 / <1
Weight loss (asthenia) 17 1 – 33 3 / <1
Fatigue/ Weakness 21 – – 31 5 / 0
Diarrhea 13 2 – 31 1 / 0
Nausea 15 – – 26 1 / 0
Mucositis 13 2 – 19 1 / 0
Dyspnea 12 – – 24 6 / 1
Pneumonitis 11 2 1 14 4 / 0
Decreased hemoglobin 73 21 6 91 9 / <1
Elevated creatinine 43 5 1 46 <1 / 0
Elevated liver transaminases 21 4 1 25–21 0–1
Elevated glucose level 53 6 – 50 12 / 0
Elevated cholesterol 45 3 – 76 3 / 0
Elevated lipid 37 4 – 71 <1 / 0
Hypothyroidism/ hyperthyroidism <1 / <1 – – – –
n number of analyzed patients
Table 5 Factors influencing the outcome of everolimus therapy
Specifications PFS ± SE (months) p -value OS ± SE (months) p -value
Gender Man/Woman 5.3 ± 0.7/ 6.4 ± 1.7 0.929 19.9 ± 3.5 /18.2 ± 2.7 0.544
Number of metastatic organs 1 / More 5.3 ± 1.5/ 5.5 ± 1.0 0.660 18.0 ± 1.9/16.6 ± 3.2 0.186
Only lung met. / Other met. 4.2 ± 0.5/ 6.4 ± 0.9 0.116 15.5 ± 3.1/21.9 ± 6.6 0.916
Presence / Lack of lung met. 5.3 ± 0.6 / 9.1 ± 2.8 0.042 10.3 ± 1.1 / 15.9 ± 4.7 0.006
ECOG status 0–1 / 2–3 6.4 ± 1.1/ 3.5 ± 0.2 0.033 19.9 ± 6.7/7.5 ± 0.6 0.008
Duration of TKI therapy (months) ≤3 / >3 3.4 ± 0.6/ 5.9 ± 0.8 0.250 16.0 ± 4.5/ 19.9 ± 5.9 0.244
≤6 / >6 4.7 ± 0.8/ 6.4 ± 1.3 0.090 21.9 ± 7.2/ 16.6 ± 2.4 0.840
≤9 / >9 4.5 ± 0.8/ 7.2 ± 1.5 0.019 16.0 ± 2.8/ 41.2 ± 18.6 0.045
Type of TKI SU / SO / PA 5.5 / 6.9 / 2.8 0.140 18 / 19.9 / 30.9 0.690
Period between TKI–EVE (days) ≤30 / >30 6.5 ± 0.9/ 5.3 ± 0.9 0.774 11.5 ± 5.4/ 30.9 ± 6.8 0.106
≤60 / >60 5.6 ± 0.6/ 4.5 ± 1.3 0.601 19.9 ± 4.9/ 16.5 ± 6.8 0.624
Anemia G0 / G1–2-3 4.8 ± 1.2/ 6.4 ± 1.0 0.612 30.9 ± 6.1/16.2 ± 1.4 0.020
PFS (months) <12 / ≥12 – – 15.5 ± 1.8/41.2 ± 9.5 0.001
ECOG Eastern Cooperative Oncology Group, EVE everolimus, G grade, met –metastasis, OS median overall survival, PA pazopanib, PFS median
progression-free survival, SE standard error, SO sorafenib, SU sunitinib, TKI tyrosine kinase inhibitor
Significant level is: p < 0.05
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statistically significant (p = 0.250 and p = 0.244, respectively).
PFS and OS were more favorable for patients who received
everolimus after receiving TKI therapy for >9 months (PFS
p = 0.019, OS p = 0.045) and for patients with an ECOG
performance status of 0 or 1 (PFS p = 0.033, OS p = 0.008).
The presence of anemia predicted a poorer survival rate
(p = 0.020), while a PFS >12 months was a favorable prog-
nostic factor (p = 0.762) [Table 5]. Only 25.5% of the patients
received third-line therapy: progesterone derivatives (17.9%),
a TKI in a clinical study (4.1%), and INF therapy (3.5%). OS
was not significantly different between patients who received
these specific third-line therapies and patients who did not
receive oncological therapy after everolimus (post EVE ther-
apy) (p = 0.001). Examining the effect of ECOG performance
status and anemia on survival, the most favorable median OS
was observed for patients without anemia and with an ECOG
performance status of 0 or 1 (30.9 ± 2.5 months), whereas it
was the most unfavorable median OS observed in patients
with anemia and with an ECOG performance status of 2 or
3 (7.7 ± 4.5 months) (p = 0.029). None of other patient or
therapy related parameters influenced PFS or OS [Fig. 1].
Discussion
Modifying the mTOR signal transduction pathway by blocking
the proliferation, migration, growing and survival and by indi-
rectly inhibiting VEGF is an important therapeutic strategy of
hypervascular RCCs [3]. EVE as an orally administered mTOR
serine/threonine kinase inhibitor shows efficiency in second-
and third-line therapies of patients with mRCC after failure of
at least one VEGFR-TKI. The safety profile of the drug is fa-
vorable. No clear predictive biomarkers are known related to
efficacy of EVE. The real world data could confirm results of
registration studies and help understand the integration of novel
drugs into the daily routine practice.
Values of our retrospective post-registration study with
EVE are the multicenter data processing, the high case num-
ber in comparison to the population, and the homogeneity of
the patients regarding previous therapies.
In our analysis, EVE monotherapy was associated with fa-
vorable PFS and OS in patients with mRCC refractory to pre-
vious VEGFR-TKI therapy. Our reported median PFS of
5.3 months is slightly longer than themedian PFS of 4.9 months
reported in the RECORD-1 registration study [4], and similar to
the median PFS of 5.4 months reported in the subgroup of
RECORD-1 patients, who had previously received only one line
of TKI therapy [9]. The median OS of patients in our study was
16.2 months. In RECORD-1, the median OS was 14.8 in the
everolimus arm [8]. Based on the previous details, results of
survival data in our study are comparable to the results of the
registration study and even the EVE standard arm in recent
clinical studies (Checkmate 025 PFSEVE: 4.4 months, OSEVE:
19.6 months), METEOR (PFSEVE: 3.9 months, OSEVE
16.5 months), LEN-EVE (PFSEVE: 5.5 months, OSEVE:
17.5 months) [13–16] [Table 1].
Regarding PFS, as an indicator of the efficiency of an active
agent, results from the everyday practice can be compared with
and do not differ significantly from the newly published results.
Overall survival data that refer to efficiency of therapeutic se-
quences based on new results suggest that introducing new ther-
apeutic options positively affect the OS [4, 13, 14].
In the registration studies and retrospective analyses of
EVE, and new active agents (carbozantinib and nivolumab),
the safety profiles were homogenous [4, 13, 14, 22].
In our study, the mean duration between ceasing VEGFR-
TKI treatment and initiating everolimus therapy was 97.7 days.
There were several reasons for delaying the start of the admin-
istration of everolimus, including resolving AEs associated with
VEGFR-TKI therapy to at least to grade 1, stabilizing symptoms
caused by new metastases (if necessary cerebral
metastasectomy, brain or bone irradiation), patient flow between
the institutes, organizing radiological examinations, and drug
Fig. 1 Effect of ECOG status and
anemia on overall survival.
Kaplan-Meier analysis of OS was
compared in patients with anemia
and ECOG 2–3 status
(7.7 ± 4.5 months) vs the absence
of anemia and ECOG 0–1 status
(30.9 ± 2.5 months) vs only one
unfavorable prognostic factor is
present (16.2 ± 3.7 months)
(p = 0.029). (ECOG – Eastern
Cooperative Oncology Group,
OS – overall survival, SE – stan-
dard error)
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availability. The length of time between TKI and mTOR inhib-
itor therapies was similar to the time between ending TKI ther-
apy and beginning everolimus following progression on placebo
in the RECORD-1 study. Surprisingly, despite the length of time
between TKI-EVE, we could not have proven any unambigu-
ous, negative effect of it in our population.
We also investigated parameters that could influence the
efficacy of everolimus.
Patients’ favorable general condition (ECOG 0–1) was asso-
ciated with a longer PFS and OS. The lack of anemia was
associated with longer survival. After the introduction of new,
registered therapeutic options, analysis of these prognostic fac-
tors might be useful during the evaluation of early experience.
We did not find a correlation between patients’ other gen-
eral characteristics, the type of previous TKI therapy or and its
therapeutic outcome. We also evaluated the effect of primary
resistance to VEGFR-TKI therapy on subsequent everolimus
efficacy. Although differences were not statistically signifi-
cant, PFS and OS tended to be less favorable in patients
who experienced primary TKI resistance. Similar results have
been reported in international studies [23]. Similarly to our
results, Bergmann et al. found no correlation between the type
or duration (< or >3 or 6 months) of previous TKI therapy and
the efficacy of everolimus in VEGF-refractory patients with
mRCC [24]. In our study, we found that patients whose
VEGFR-TKI therapy was >9 months had significantly more
favorable PFS and OS [24].
The prognostic score system published by Motzer for
second-line therapy demonstrated unfavorable prognosis in
the presence of 3 factors: anemia, poor general health
(Karnofsky performance status <80), and a high level of
corrected calcium (>10 mg/dL or >2.4 mmol/L), instead of
the 5 factors used to determine prognosis for first-line therapy
[25]. In our population, we demonstrated that poor general
health negatively influenced survival. If the patients’ general
condition was good, and they did not have anemia, the OSwas
30.9 months, but if they had poor health and anemia, OS time
decreased to 7.7 months. In our analysis, we found that ECOG
performance status was one of the most important factors that
affect PFS. OS was remarkably better in patients with a dura-
tion of everolimus therapy >12 months. This underlines the
importance of appropriate patient selection. After longer du-
ration of everolimus therapy, the number of third-line thera-
pies decreased without influencing survival, so the properly
selected, effective second-line therapy determined the pa-
tients’ life expectancy.
Conclusions mTOR inhibition is an effective way to treat
patients with VEGFR-TKI refractory mRCC. According to
experience in the Hungarian everyday practice, VEGFR-TKI
refractory patients in good general health, having adequate
hematological values, and >9 months of previous VEGFR-
TKI therapy may experience delayed disease progression
and improved survival while maintaining good quality of life
during the second-line everolimus therapy. Despite the more
favorable efficiency of new, registered drugs, EVE therapy
still plays role during and after second-line therapy for
mRCC in regions where modern remedies are only limitedly
available, they have not been introduced yet, or their admin-
istration is contraindicated due to medical reasons.
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